Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim
Author:
Affiliation:
1. Department of Pharmacy, University of Washington School of Pharmacy, Seattle, WA, USA
2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA
3. Sandoz Inc., Princeton, NJ, USA
Funder
Sandoz
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Health Policy,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737167.2018.1476142
Reference21 articles.
1. Worldwide experience with biosimilar development
2. Biosimilars in the United States: Emerging Issues in Litigation
3. Generic Drug Industry Dynamics
4. Biosimilars: The US Regulatory Framework
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An Institutional Guide for Formulary Decisions of Biosimilars;Hospital Pharmacy;2022-11-29
2. Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018;Journal of Managed Care & Specialty Pharmacy;2021-05
3. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives;Applied Health Economics and Health Policy;2021-01-28
4. Recognizing barriers to entry of biosimilars in the United States market and highlighting the solutions;Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector;2020-11-08
5. Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions;PharmacoEconomics - Open;2020-06-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3